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ABSTRACT Sporadic literature reports describe isolates of pathogenic bacteria that
harbor an antibiotic resistance determinant but remain susceptible to the corre-
sponding antibiotic as a consequence of a genetic defect. Such strains represent a
source from which antibiotic resistance may reemerge to cause treatment failure in
patients. Here, we report a systematic investigation into the prevalence and nature
of this phenomenon, which we term silencing of antibiotic resistance by mutation
(SARM). Instances of SARM were detected among 1,470 Staphylococcus aureus isolates
through side-by-side comparison of antibiotic resistance genotype (as determined by
whole-genome sequencing) versus phenotype (as assessed through susceptibility test-
ing). Of the isolates analyzed, 152 (10.3%) harbored a silenced resistance gene, including
46 (3.1%) that exhibited SARM to currently deployed antistaphylococcal drugs. SARM re-
sulted from diverse mutational events but most commonly through frameshift mutation
of resistance determinants as a result of point deletion in poly(A) tracts. The majority
(90%) of SARM strains reverted to antibiotic resistance at frequencies of 109; thus,
while appearing antibiotic sensitive in the clinical microbiology laboratory, most S. au-
reus isolates exhibiting SARM will revert to antibiotic resistance at frequencies achievable
in patients. In view of its prevalence in a major pathogen, SARM represents a signiﬁcant
potential threat to the therapeutic efﬁcacy of antibiotics.
IMPORTANCE Antibiotic resistance hinders the treatment of bacterial infection. To
guide effective therapy, clinical microbiology laboratories routinely perform suscepti-
bility testing to determine the antibiotic sensitivity of an infecting pathogen. This ap-
proach relies on the assumption that it can reliably distinguish bacteria capable of
expressing antibiotic resistance in patients, an idea challenged by the present study.
We report that the important human pathogen Staphylococcus aureus frequently car-
ries antibiotic resistance genes that have become inactivated (“silenced”) by muta-
tion, leading strains to appear antibiotic sensitive. However, resistance can rapidly
reemerge in most such cases, at frequencies readily achievable in infected patients.
Silent antibiotic resistance is therefore prevalent, transient, and evades routine de-
tection, rendering it a signiﬁcant potential threat to antibacterial chemotherapy.
KEYWORDS silenced antibiotic resistance, SARM, Staphylococcus
Antibiotic resistance is dramatically undermining our ability to treat bacterial infec-tion and constitutes a serious threat to public health (1). As the prevalence of
antibiotic resistance increases among bacterial pathogens, so too does the importance
of the role played by the clinical microbiology laboratory in determining which antibacterial
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drugs retain sufﬁcient activity against a given isolate to offer potential therapeutic
beneﬁt. The gold standard approach for establishing this information is susceptibility
testing, i.e., challenging the isolate with an antibacterial drug and assessing whether
bacterial growth can be inhibited at concentrations likely to be achievable in vivo. This
approach relies on the assumption that such testing will reliably distinguish bacteria
capable of expressing antibiotic resistance in a patient. Unfortunately, this assumption
does not always hold true.
Sporadic reports exist of bacteria harboring antibiotic resistance determinants that
have become inactivated by a genetic defect (2–6), a phenomenon we term “silencing
of antibiotic resistance by mutation” (SARM). By deﬁnition, strains subject to SARM
ordinarily fail to express antibiotic resistance, and will therefore be classiﬁed as antibi-
otic sensitive upon susceptibility testing. However, SARM may in some cases be reversible
(4, 5), thereby allowing the rapid reemergence of antibiotic resistance in an apparently
antibiotic-susceptible strain. Where reversion of SARM to full phenotypic resistance
occurs during treatment of infection with the corresponding antibacterial drug, this
would prompt an unanticipated therapeutic failure. Indeed, a recent study described a
case of such reversion to resistance occurring in a patient with the resultant failure of
antibiotic treatment (6).
Information is currently lacking regarding the prevalence and scope of SARM in
bacterial pathogens or the extent to which it is reversible; an appreciation of these
aspects will be required to enable an assessment of the likely clinical impact of SARM
on the effectiveness of antibacterial chemotherapy. We report here the ﬁrst large,
systematic screen to identify instances of SARM in an important bacterial pathogen of
humans (Staphylococcus aureus). Our ﬁndings establish that SARM is prevalent, affects
a broad range of antibiotic resistance determinants, and results from diverse genetic
events that prevent expression of a functional resistance protein. Crucially, we dem-
onstrate that SARM is in most cases readily reversible, revealing this phenomenon as an
important potential source of therapeutic failure in the treatment of bacterial infection.
RESULTS
Prevalence of SARM in clinical isolates of S. aureus. This study employed a
collection of 1,470 S. aureus strains, most of which were recovered as the causative
organism from human infections, and all of which are multidrug resistant (deﬁned here
as resistant to two or more clinically deployed antibacterial drug classes). The entire
collection was subjected to susceptibility testing using a panel comprising the major
antistaphylococcal drug classes in clinical use, and was in parallel subjected to whole-
genome sequencing (WGS), de novo genome assembly, and in silico detection of
acquired antibiotic resistance genes using the ARIBA tool. Staphylococci that appeared
antibiotic sensitive according to published clinical breakpoints but harbored a cognate
resistance gene were considered potential examples of SARM. However, some antibi-
otic resistance determinants (e.g., blaZ,mecA, and ermA) are known to require induction
for resistance to manifest, and care was therefore taken to ensure that apparent
instances of discordance between resistance genotype and phenotype did not simply
constitute a failure to induce resistance. To assess this, all potential SARM isolates were
preincubated with subinhibitory concentrations of the relevant antibiotic for 1 h before
subjecting them to repeat susceptibility determinations.
Strains exhibiting SARM were identiﬁed for the aminoglycosides (involving the
resistance genes aacA-aphD and ant4), -lactams (cefoxitin [mecA] and penicillin [blaZ]),
clindamycin [vga(A)v], erythromycin (ermA), mupirocin (mupA), quinupristin-dalfopristin
(Q/D) [vga(A)v together with ermA or ermC], and tetracycline (tetK and tetM) (Table 1).
In total, 46 (3.1%) of the isolates exhibited SARM to currently deployed antistaphylo-
coccal drugs (Fig. 1), with one isolate (NRS752) harboring two silenced resistance genes
(mecA and blaZ) (Table 1). We additionally identiﬁed numerous instances of SARM to
spectinomycin, an antibiotic that is not used clinically to treat staphylococcal infection
in humans but is employed for the treatment of gonorrhea and a variety of bacterial
infections encountered in veterinary medicine (7, 8); ARIBA detected 21 strains with an
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apparently inactivated version of the spectinomycin resistance gene, aad9, which were
conﬁrmed in subsequent susceptibility tests to be spectinomycin sensitive (Table 1).
ARIBA analysis also identiﬁed instances of mutationally inactivated resistance genes in
strains exhibiting no discordance between genotype and phenotype, a situation at-
tributable to the presence in those strains of a second, intact resistance gene that
phenotypically masked the effect of SARM (see Table S1 in the supplemental material).
Accordingly, we designated this phenomenon “masked SARM” (mSARM) to distinguish
it from “true” SARM that impacts antibiotic resistance phenotype. For example, strain
MOS330 harbored a tetM gene inactivated by a frameshift mutation, but it also carried
an intact tetK gene that conferred resistance to tetracycline. Most strikingly, we
identiﬁed 83 strains carrying apparently inactivated blaZ or blaRI genes but which were
nonetheless resistant to penicillin owing to the fact that they also carried mecA
(Table S1). Considering all examples of SARM and mSARM together, phenotypically
silent antibiotic resistance genes were detected in 152 (10.3%) of the 1,470 strains
analyzed.
Mutational events responsible for gene silencing in SARM strains. For approx-
imately 70% (48 of 67) of SARM isolates, genetic changes were identiﬁed within either
the coding region or the expression/regulatory elements of the resistance gene that
could account for failure to produce a functional antibiotic resistance protein (Table 1).
The genetic changes underlying SARM were diverse, running the gamut of common
mutational events. In the majority of cases, SARM was the result of point mutations
(insertions, deletions, and substitutions), though larger deletions and insertions involv-
ing integration of transposable elements were also identiﬁed (Fig. 2). The most com-
mon type of mutation identiﬁed was nucleotide deletion, which in all instances involved
the loss of a single nucleotide from a poly(A) tract. Such mutations, which are thought
to result from slippage of DNA polymerase during replication of these tracts (9), have
previously been reported in isolated cases of SARM (6, 10). Collectively, the genetic
changes identiﬁed resulted in loss of resistance gene function in a variety of ways, but
frequently as a result of frameshift (Table 1 and Fig. 2).
FIG 1 Prevalence of SARM to clinically deployed antibacterial drugs in S. aureus. The numbers of SARM
strains identiﬁed for given agents are shown as black bars (left y axis), while the red bars (right y axis)
show this value as a percentage of the total number of isolates exhibiting phenotypic resistance to that
drug in this study. Two of the aminoglycoside SARM strains identiﬁed carry a silenced aacA-aphD gene
that confers resistance to multiple aminoglycosides and have therefore been included in the total
number of instances of SARM for both gentamicin and tobramycin.
Kime et al. ®
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Reversion to phenotypic antibiotic resistance in strains exhibiting SARM. To
assess the potential for SARM strains to revert to phenotypic antibiotic resistance, we
challenged representatives of all distinct SARM genotypes (and all strains in which the
basis for SARM could not be deﬁned) with the corresponding antibacterial agent at
concentrations of 4 MIC. The majority (90%) of SARM strains yielded antibiotic-
resistant colonies upon challenge, at frequencies between 104 and 1010 (Table 2).
Among strains for which a likely genetic basis for SARM had been deﬁned, 96%
showed reversion to phenotypic antibiotic resistance. Genetic characterization of re-
vertants revealed that loss of SARM was often the result of direct reversion of the
original silencing mutation (Table 2). The frequency of reversion of SARM resulting from
shortening of poly(A) tracts was proportional to tract length, with longer tracts revert-
ing more readily (see Fig. S1 in the supplemental material); this is as expected if
reversion results from slipped-strand mispairing, since the opportunity for such events
to occur will increase the longer the tract.
Representative examples of mutational events underlying reversion of SARM.
SARM strain GAL218 harbors the aacA-aphD gene that encodes the bifunctional
aminoglycoside modifying enzyme AAC(6=)-APH(2==) and that ordinarily confers resis-
tance to both gentamicin and tobramycin. DNA sequence analysis of this strain
identiﬁed the presence of an IS256 transposable element inserted between nucleotides
834 and 835 of this gene, which thereby prevented expression of an intact resistance
protein (Fig. 3A). Reversion to gentamicin and tobramycin resistance occurred at
frequencies of 107 to 108 as a result of spontaneous excision of IS256 to restore the
integrity of the gene (Table 2 and Fig. 3A).
SARM can result from a single missense mutation in the coding region of an
antibiotic resistance determinant. Such a genetic defect was found in strain NRS720
within ermA, a gene encoding a methyltransferase that modiﬁes rRNA to mediate
erythromycin resistance. Nucleotide substitution G112A produced amino acid change
G38R within the ErmA binding pocket for the cosubstrate, S-adenosyl-L-methionine
(SAM), with resultant loss through substitution of a residue essential for enzyme activity
(Fig. 3B) (11). Revertants exhibiting high-level erythromycin resistance were selected
upon challenge with the antibiotic at frequencies of 109, and sequence analysis of
the ermA gene conﬁrmed direct reversion of the original mutation to reinstate G38
(Table 2 and Fig. 3B).
In the absence of functional MecRI-MecI regulatory proteins, expression of the
methicillin resistance genemecA can be regulated by the homologous BlaRI-BlaI system
FIG 2 Genetic changes underlying SARM to clinically deployed antistaphylococcal drugs and the mechanism by
which these changes lead to gene silencing. Classes of mutational event leading to antibiotic resistance gene
silencing in SARM strains, and the number of examples detected in each case, are shown on the inner (colored)
chart. The consequence of these changes for expression of the resistance gene is indicated on the outer (gray-scale)
ring.
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(12, 13). In SARM strain NRS752, the MecI transcriptional repressor is absent, and
expression of mecA is subject to repression by BlaI. However, the sensor/signal trans-
ducer gene (blaRI) in that strain contains a single nucleotide deletion within a poly(A)
tract that results in a frameshift mutation (Table 1 and Fig. 3C); sensing of antibiotic and
consequent proteolysis of BlaI is therefore impaired, and mecA expression is subject to
continual repression. Cefoxitin-resistant revertants were selected at high frequency
(106) upon challenge with antibiotic and resulted from complete loss of the blaZ-
blaRI-blaI operon in two of three revertants analyzed (Table 2 and Fig. 3C).
Reversion to antibiotic resistance in strains exhibiting SARM can also occur through
suppression, an indirect mechanism in which the original silencing mutation remains,
but compensatory mutation allows expression of a functional resistance protein. A
guanine nucleotide inserted into mecA between positions 229 and 230 was responsible
for inactivating this gene by frameshift mutation in SARM strain GAL206 (Table 1).
Analysis of three cefoxitin-resistant revertants recovered following selection with the
TABLE 2 Reversion to antibiotic resistance in SARM strainsa
Antibacterial
drug tested
Resistance
gene(s)
Representative
strain tested
for reversion
Reversion
frequency
Revertant MIC
(mg/liter)/fold
increase relative
to SARM strain Mechanism of reversion
Gentamicin aacA-aphD GAL218 2.9 (1.1)  108 32/128-fold Excision of transposable element IS256
Tobramycin aacA-aphD GAL218 8.5 (1.3)  107 16/32-fold Excision of transposable element IS256
ant4 MOS258 8.1 (2.7)  1010 64/256-fold Deletion of nucleotide G60; amino acid
change K20Q
Spectinomycin aad9 NRS256 6.6 (6.3)  109 512/8-fold Direct reversion of original mutation
aad9 MOS430 1.8 (0.7)  106 512/8-fold 1. Direct reversion of original mutation
2. T724C; amino acid S242Q
aad9 MOS427 9.2 (6.3)  107 512/8-fold 1. Direct reversion of original mutation
2. C298A; amino acid Q100K
Cefoxitin mecA GAL206 2.9 (1.9)  109 64/16-fold 1. Deletion of C222; amino acid V75L
2. Deletion of A228; no coding change
3. Deletion of A232; amino acid D77G and I78L
mecA SG138 1.1 (0.2)  104 32/8-fold Unknown
mecA NRS752 4.0 (2.1)  106 32/8-fold Loss of bla operon in 2 out of 3 revertants
analyzed
Penicillin blaZ NRS752 1.4 (1.3)  106 8–16/256- to
512-fold
Unknown
Clindamycin vga(A)v MOS244 2.2 (1.1)  109 1/4-fold Increased copy number of Tn5406
[carries vga(A)v] from ﬁve to six
Erythromycin ermA MOS55 4.8 (1.7)  1010 None recovered Not applicable
ermA MOS283 4.4 (1.7)  107 256 (induced by
erythromycin)/
512-fold
Excision of transposable element IS256
ermA MOS287 1.9 (1.3)  107 256 (induced by
erythromycin)/
512-fold
Direct reversion of original mutation
ermA NRS720 1.4 (0.6)  109 256 (constitutive)/
512-fold
Direct reversion of original mutation
Q/D vga(A)v/ermC MOS98 1.4 (1.1)  109 8/8-fold Unknown
vga(A)v/ermA MOS119 ~9  1010 8/8-fold Unknown
Tetracycline tetK NRS699 5.1 (1.8)  106 64/128-fold Unknown
tetM MOS22 7.9 (3.3)  108 128/128-fold Direct reversion of original mutation
Mupirocin mupA DUB36 1.4 (1.1)  107 256/512-fold Direct reversion of original mutation
aReversion studies were conducted using a single strain corresponding to each distinct SARM genotype, and reversion frequencies are expressed as means 
standard deviations. For MOS119, revertants were not recovered in all determinations, and consequently only an approximate reversion frequency is given.
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FIG 3 Representative examples of genetic events leading to reversion of SARM in S. aureus. (A) The diagram (left) shows the basis for
SARM in S. aureus GAL218 (refer to text for details). (Right) PCR ampliﬁcation with oligonucleotide primers P1 and P2 generated a PCR
product of 1.7 kb from this strain (lane 1). Reversion to phenotypic resistance was associated with excision of this transposable
element, as revealed by the generation of a smaller PCR amplicon (370 bp) from the revertant (lane 2). The lane labeled M contains
1-kb Hyperladder (Bioline). (B) Reversion of SARM in strain NRS720. The genetic defect in the ermA gene is shown boxed, with nucleotide
numbers relative to the translation start codon indicated above the sequences and amino acid numbers shown below the sequences.
(C) The diagram (left) shows the basis for SARM in strain NRS752 (see the text for details). (Right) The blaZ-blaRI (lanes 1; 950-bp) and
blaI (lanes 2; 300-bp) genes could be ampliﬁed by PCR from the SARM strain but were absent in a cefoxitin-resistant revertant.
Ampliﬁcation of the spa gene (lanes 3;450 bp) provided a PCR control. (D) Basis for reversion of SARM in strain GAL206. The nucleotide
and amino acid sequences are labeled as in panel B, with amino acids that differ from those in the wild type shown in gray-scale. The
insertion inactivatingmecA in this strain is highlighted in yellow, and the nucleotide that has become deleted in each revertant to restore
phenotypic resistance is indicated in the wild-type sequence in the corresponding color.
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antibiotic revealed each to have undergone deletion of a different nucleotide in the
vicinity of the original insertion site (C222, A228, and A232) to restore the reading frame
and allow production of a functional resistance protein (Table 2 and Fig. 3D). These
mutations resulted in minor coding changes in two of the three revertants relative to
the wild-type sequence (V75L and D77G/I78L), but these changes did not appear to
impair the ability of the protein to mediate cefoxitin resistance.
Clonality and context of isolates harboring silenced antibiotic resistance genes.
Existing, publicly available collections of S. aureus genomes were compiled to contex-
tualize isolates analyzed in this study and included collections with a high diversity of
S. aureus clonal complexes (14–17) and those comprising isolates from the same clonal
complex but broad geographical coverage (18–23). Subsequent construction of RAxML
phylogenies (24) allowed determination of the clonality of SARM/mSARM isolates and
delineated their relationship to S. aureus strains from European and global collections.
Of the 67 SARM isolates, 39 (~58%) clustered with at least one other isolate with an
identical SARM genotype, implying clonality (Table S1). This value rose to ~72%
(110/152) when considering all isolates (both SARM and mSARM) that harbor a silenced
antibiotic resistance gene (Table S1). Contextual isolates revealed that two clades
carrying silenced antibiotic resistance genes are widely spread geographically; a large
monophyletic clade made up of mostly ST228 and ST111 isolates (clonal complex 5
[CC5]) spanning Europe and Israel (n 56 SARM isolates) (Fig. 4A) and a large CC8 clade
made up of mostly ST239 isolates (n 23) (Fig. 4B), spanning multiple European
countries. In view of the fact that the CC5 clone exhibits mSARM and the CC8 clade is
predominantly associated with SARM to an antibiotic not used to treat staphylococcal
infection in humans (spectinomycin), resistance gene silencing in these clades does not
for the most part have obvious clinical relevance. The other clades identiﬁed were
smaller (2 to 11 isolates) and restricted to the same country (Table S1), demonstrating
that SARM/mSARM occur across a diverse background of S. aureus clades.
DISCUSSION
We report here that silenced antibiotic resistance genes are prevalent in one of the
major bacterial pathogens of humans, occurring in 10% of S. aureus isolates tested,
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including 3.1% that exhibit SARM to currently deployed antistaphylococcal agents.
Carriage and expression of antibiotic resistance genes are known to exact a ﬁtness cost
on bacteria in antibiotic-free environments (25), and the phenomenon of SARM can be
understood in terms of counterselection of these costly determinants when not re-
quired. Key to assessing the potential medical impact of these ﬁndings is whether this
loss of resistance occurs primarily in the clinic or is instead an event that takes place
during passage or storage of these strains in the laboratory after isolation. The independent
recovery of closely related S. aureus isolates with identical SARM genotypes strongly
supports the idea that SARM preexisted laboratory isolation in these cases, and thereby
implies that—at minimum—58% of SARM strains identiﬁed in this study arose in the
clinical environment (Table S1).
The genetic basis for SARM could be deﬁned in the majority of isolates analyzed,
usually involving mutations lying within—or upstream of—the antibiotic resistance
determinant that prevented expression of a functional resistance protein. However, the
basis for SARM remains undeﬁned in a minority of isolates that harbor intact antibiotic
resistance genes associated with appropriate/undamaged upstream expression signals
(Table 1). In a proportion of the latter isolates, it could be that as-yet-unidentiﬁed
trans-acting elements are responsible for silencing resistance; in line with this idea, such
elements have previously been implicated in silencing of plasmid-borne antibiotic
resistance genes in Escherichia coli strains recovered from animal experiments (26). In
most cases, however, a more prosaic explanation exists. Our study identiﬁed several
strains carrying an apparently wild-type (i.e., fully functional) version of the vga(A)v
gene but which nonetheless exhibited susceptibility to clindamycin. WGS analysis of a
clindamycin-resistant variant recovered from one of these strains upon selection de-
tected an increase from ﬁve to six in the copy number of Tn5406 [the transposable
element that carries vga(A)v] (Table 2), a change that appears to cause resistance by
increasing the gene dosage of vga(A)v. While this ﬁnding does not exclude the
possibility that this genetic change is acting to overcome a silencing mutation/element
lying distant from the resistance gene, we consider it more likely that expression of
vga(A)v is ordinarily simply insufﬁcient to confer clinically signiﬁcant resistance to
clindamycin in these strains (i.e., resistance gene expression is suboptimal rather than
silenced by mutation) (27) and that resistant variants recovered upon antibiotic chal-
lenge are gain-of-function mutants rather than revertants. Suboptimal—rather than
silenced—resistance gene expression would also appear a more plausible explanation
for the observation that 58% (7 of 12) of strains found to carry the genes for resistance
to Q/D were nonetheless susceptible to the drug, a value an order of magnitude greater
than that for SARM cases detected for the other antibacterial drug classes tested (Fig. 1).
If lack of an antibiotic resistance phenotype in some of these strains is indeed the
consequence of suboptimal resistance gene expression, then they would not—by
deﬁnition—qualify under the heading of SARM. Nevertheless, the implications for
potential therapeutic failure are ultimately the same whether phenotypic antibiotic
resistance becomes reinstated in such strains through reversion of true SARM or occurs
for the ﬁrst time through de novo activation of a previously cryptic resistance genotype.
SARM can be irreversible, involving a permanent loss of antibiotic resistance, or
reversible; the latter implies that phenotypic resistance may be regained and that
silencing of resistance in such cases must therefore be considered effectively transient.
In the overwhelming majority of strains, SARM was found to be reversible, yielding
progeny exhibiting phenotypic antibiotic resistance upon challenge with the corre-
sponding antibiotic. SARM reversion occurred at frequencies (generally 109) readily
attainable within bacterial populations during infection (28). Indeed, antistaphylococcal
drugs that select resistance at similar frequencies (e.g., rifampin, fusidic acid) are rarely
used as monotherapy for serious infections precisely to avoid therapeutic failure
resulting from resistance development during the treatment interval (29). Furthermore,
as indicated above, reversion to antibiotic resistance in a SARM isolate has been docu-
mented in a patient during treatment (6). Thus, most of the SARM strains identiﬁed in
this study would be anticipated to revert to full phenotypic antibiotic resistance in
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patients upon initiation of therapy with the corresponding antibacterial drug, with
consequent therapeutic failure.
The ﬁnding that SARM is both prevalent and frequently reversible in a major
bacterial pathogen challenges a key assumption of in vitro susceptibility testing: that it
represents a reliable predictor of the microbiological response to an antibacterial drug
in vivo. Since susceptibility testing cannot discriminate truly antibiotic-sensitive isolates
from those exhibiting SARM, it will in a proportion of cases support the clinical
deployment of an antibacterial drug to treat infection for which therapeutic failure lies
only a reversion event away. In effect, SARM represents a class of “hidden” antibiotic
resistance that evades routine detection, and therefore has parallels with the recently
dissected phenomenon of heteroresistance (30). There is no easy ﬁx for this issue at
present, given that the methods by which SARM can be detected are not generally
feasible in the context of the clinical microbiology laboratory. However, growing
interest in—and proof of principle for—the use of WGS to predict antibiotic resistance
in silico suggests that DNA sequencing could ultimately supplant routine susceptibility
testing, a development that would address the problem (14, 31); detection of antibiotic
resistance by genotype irrespective of phenotype has its own limitations and pitfalls,
but it does have the beneﬁt of identifying potential SARM strains. Until such time, we
recommend that, wherever practicable, SARM be investigated as a potential cause in
cases of unanticipated therapeutic failure in the treatment of bacterial infection.
MATERIALS AND METHODS
Bacteria used in this study. To ensure maximal diversity, S. aureus isolates were sourced from a
broad range of clinical and geographical settings. We employed three major preexisting collections of
S. aureus; an established resource comprising diverse isolates held at the University of Leeds (n 320)
(32), a subset of isolates from the NARSA collection (n 241; https://www.beiresources.org/), and a set
of 496 methicillin-resistant S. aureus (MRSA) strains collected by the MOSAR consortium from sites across
Europe and Israel (33–35). Further isolates were obtained from several United Kingdom sites that
included St. Georges NHS Trust, London (n 157), the Royal Veterinary College, Hertfordshire (n 87),
and hospitals in the Republic of Ireland (n 169). The majority of strains were isolated from human
patients (n 1437), with a small number deriving from animal sources (n 33). The laboratory strain
S. aureus SH1000 was used as an antibiotic-susceptible control organism (36).
Media, antibiotics, and susceptibility testing. MICs were determined by agar dilution according to
CLSI guidelines (37), using cation-adjusted Mueller-Hinton agar (MHA) (Becton, Dickinson) and broth
(MHB) (Sigma-Aldrich). To facilitate susceptibility testing of the entire strain collection, only a small range
of antibacterial drug concentrations around the EUCAST clinical breakpoints were employed to distin-
guish sensitive and resistant isolates in the ﬁrst instance (38). Susceptibility determinations were performed
with the following antistaphylococcal drugs: aminoglycosides (gentamicin and tobramycin), glycopep-
tides (teicoplanin and vancomycin), -lactams (cefoxitin and penicillin), macrolides/lincosamides/strep-
togramins (clindamycin, erythromycin, and quinupristin-dalfopristin [Q/D]), oxazolidinones (linezolid),
tetracycline, and miscellaneous agents (chloramphenicol, fosfomycin, fusidic acid, mupirocin, and trim-
ethoprim). In addition, susceptibility determinations with spectinomycin were performed on selected
strains. All drugs were obtained from Sigma-Aldrich, with the exception of linezolid, tobramycin, and
vancomycin (Cayman Chemical), penicillin (Fisher Scientiﬁc), and Q/D (Santa Cruz Biotechnology).
Whole-genome sequencing and detection of resistance determinants. Whole-genome sequenc-
ing (WGS) of S. aureus isolates was performed at the Wellcome Sanger Institute, UK. DNA libraries (450-bp
insert size) were generated and sequenced using 100-bp paired-end reads on the Illumina HiSeq2000
platform, essentially as described previously (39). De novo genome assembly was performed as previ-
ously described (40), and sequence data were deposited with the European Nucleotide Archive (www
.ebi.ac.uk/ena; accession numbers listed in Table S2 in the supplemental material). Assembled genomes
were interrogated for acquired resistance genes using the Antimicrobial Resistance Identiﬁcation By
Assembly (ARIBA) tool (41), employing a custom-made database (Table S3) comprising only horizontally
acquired genes documented to confer antibiotic resistance in staphylococci. The genetic basis for SARM
was explored through analysis of genome sequence data and conﬁrmed by PCR ampliﬁcation (using
Phusion DNA polymerase [New England Biolabs] according to the manufacturers’ instructions and
oligonucleotide primers listed in Table S4), followed by DNA sequencing.
Genomic and phylogenic analyses. Publicly available collections of S. aureus genomes were
compiled to contextualize isolates analyzed in this study. These collections included a pan-European
structured survey of invasive S. aureus isolates (n 308) (14) and a global collection of strains that
represents the breadth of known clonal, geographical, and host species diversity of S. aureus (n 800)
(15), from which only human-infecting and colonizing isolates were selected (n 437 of 800). In addition
to the European and global collections, isolates were included from two large hospital-based studies
from the United Kingdom (n 1,977) (17) and Italy (n 184) (16) that capture the most common
S. aureus clonal complexes in European hospitals. These hospital studies were deduplicated to keep only
one isolate per patient (the earliest available one) and one isolate per outbreak clone (the earliest
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observed) by removing consecutive and genetically related isolates (deﬁned as having less than 50 single
nucleotide polymorphisms [SNPs] at the core genome) from different patients. We ultimately retained
491 (of 1,977) and 110 (of 184) isolates from the United Kingdom and Italian hospital studies, respec-
tively. In addition to including collections with a diversity of clonal complexes (CCs) (14–17), collections
of isolates were compiled from the same clonal complex but broad geographical coverage for clonal
complex 22 (CC22) (19), CC8 (18, 22), and CC398 (20, 23).
Short reads of all S. aureus genomes from this study and contextual collections were subjected to de
novo assembly using Velvet (42) or Spades (43), and raw assemblies were improved using an established
bacterial assembly and improvement pipeline (40). Sequence types (STs) were derived from de novo
assemblies by extracting all seven S. aureus multilocus sequence type (MLST) loci and comparing them
to the PubMLST database (www.PubMLST.org). Clonal complexes were derived from the allelic proﬁle,
allowing up to two allele mismatches from the reference ST. All isolates were mapped using SMALT v0.7.4
to the EMRSA15 ST22 reference genome (strain HO 5096 0412, GenBank accession number HE681097).
SNPs at the chromosomal regions corresponding to the core genome were kept from whole-genome
alignments, and maximum likelihood trees were created using RAxML (24) for each CC as previously
described (44). The S. aureus species core genome was derived running Roary (45) on the global
contextual collection with default settings (44), in this case using all 800 S. aureus isolates, which
consisted of 1,766 genes and covered 1.76 Mb (62%) of the EMRSA15 ST22 reference genome.
Selection and characterization of SARM revertants. Selection of antibiotic-resistant revertants
from strains exhibiting SARM was achieved by plating cultures onto MHA containing 4 to 128 MIC
of the corresponding antibacterial agent and incubating for 48 h at 37°C. To calculate reversion
frequencies, three independent cultures were sampled in triplicate to determine both revertant count
and total count (determined by plating onto drug-free MHA), and results were expressed as the mean
value for the number of revertants obtained/number of viable cells. Genetic changes were detected in
SARM revertants by PCR ampliﬁcation, followed by either DNA sequencing or sizing of PCR amplicons by
agarose gel electrophoresis.
Data availability. All sequence data have been deposited with the European Nucleotide Archive and
accession numbers are listed in Table S2.
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